Abstract:Background: Tuberculosis (TB) is a major global health problem in the whole world, especially in the developing countries. We aimed to assess diagnostic accuracy and safety of a novel ESAT6-CFP10 (EC) skin test for TB infection in Chinese adults.Methods: We conducted randomized, double-blinded, parallel-group clinical trials at two sites in healthy adults and TB/non-TB patients, respectively. TB infection-free healthy participants in a ratio of 1:1:1:1 to receive BCG vaccine or placebo, followed by EC skin test (0·5μg/0·1ml), or EC (1μg/0·1ml), along with the TST, T-SPOT.TB test, 12 weeks after the vaccination. TB patients or non-TB patients with pulmonary disease were randomly allocated in a ratio of 1:1 to receive EC skin test at 0·5μg/0·1ml, or 1μg/0·1ml, along with the TST and T-SPOT.TB test. The diameter of the skin indurations and/or redness at the injection sites were measured at 24 hours, 48 hours, and 72 hours after the skin tests. The studies was registered with ClinicalTrials.gov, number NCT02389322 and NCT02336542.Findings: We enrolled 223 TB infection-free healthy participants after screening, and randomly allocated them to receive BCG vaccination or placebo vaccination. Of them, 83 and 86 complete the EC skin test at 0·5μg/0·1ml or 1μg/0·1ml after vaccination. 96 TB patients and 95 non-TB patients with pulmonary diseases were allocated to receive the EC skin test at 0·5μg/0·1ml or 1μg/0·1ml, respectively. EC skin test at 1μg/0·1ml was found to be superior to 0·5μg/0·1ml based on the estimated AUCs, and the maximum AUCs of 0·927 was obtained at 1μg/0·1ml EC skin test at 48 hours using diameters of redness or induration as indicator. The highest diagnostic values achieved with cutoff values between 3·7~6·3 mm, and 5mm was determined as positive cutoff value for the responses of EC skin test. The incidence of adverse reaction following the EC skin tests were 27·8%, and no serious adverse event related to the EC skin tests was observed.Interpretation: The experimental EC skin test has an acceptable safety proﬁle. EC skin test at 1μg/0·1ml can achieve both high specificity and sensitivity, and was selected as optimal dose for future studies.Funding: National Science and Technology Major Project (2012ZX10004710) Zhifei Longcom Biologic Pharmacy Co., China.Declaration of Interest: We declare no competing interests.Ethical Approval: We obtained approvals from the institutional review boards of the Jiangsu Provincial Center of Disease Control and Prevention, and Shanghai Public Health Clinical Center before initiation of the studies. Written informed consent were obtained from all participants. The trials were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.

Study protocol: diagnostic accuracy study comparing Cy-Tb and STANDARD F TB-Feron FIA tests for tuberculosis infection diagnosis in Vietnam

Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa

Combination of exhaled breath condensate samples with lipoarabinomannan point of care assay for pulmonary tuberculosis (TB) diagnosis: protocol for a diagnostic accuracy study

Sensitivity, Specificity and Safety of a Novel Skin Test (ESAT6-CFP10) for Tuberculosis Infection in China: Randomized, Blinded, Self-Controlled, Parallel-Group Phase 2b Trials

Sensitivity, Specificity, and Safety of a Novel ESAT6-CFP10 Skin Test for Tuberculosis Infection in China: 2 Randomized, Self-Controlled, Parallel-Group Phase 2b Trials

Optimising diagnosis and treatment of tuberculosis infection in community and primary care settings in two urban provinces of Viet Nam: a cohort study

Diagnostic accuracy of TB screening tests in a prospective multinational cohort: Chest-X-ray with computer-aided detection, Xpert TB host response, and C-reactive protein

Head-to-head comparison of diagnostic accuracy of TB screening tests: Chest X-ray, Xpert TB host response, and C-reactive protein

High Accuracy of Recombinant Fusion Protein Early Secretory Antigenic Target Protein 6‐culture Filtrate Protein 10 Skin Test for the Detection of Tuberculosis Infection: a Phase III, Multi‐centered, Double‐blind, Hospital‐based, Randomized Controlled Trial

Evaluation of serological assays for the diagnosis of childhood tuberculosis disease: a study protocol

Evaluation of molecular diagnostic test for detection of adult pulmonary tuberculosis: A generic protocol

High Accuracy of Recombinant Fusion Protein ESAT6-CFP10 Skin Test for the Detection of Tuberculosis Infection: A Phase III, Multi-centered, Double-blind, Hospital-based, Randomized Controlled Trial

Cytokine and Antibody Based Diagnostic Algorithms for Sputum Culture-Positive Pulmonary Tuberculosis

A Retrospective Study of Factors Contributing to the Performance of an Interferon-Gamma Release Assay Blood Test for Tuberculosis Infection

Performance of a stool-based quantitative PCR assay for the diagnosis of tuberculosis in adolescents and adults: a multinational, prospective diagnostic accuracy study

Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries

Diagnosis of tuberculosis infection in children with a novel skin test and the traditional tuberculin skin test: An observational study

Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study

TB Skin Testing vs Interferon-γ Release Assays in TB Disease Prediction

Preliminary diagnostic performance of the VIDAS® TB-IGRA for the detection of Mycobacterium tuberculosis infection and disease

Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial